AI Engines For more Details: Perplexity Kagi Labs You
Staphylococcal Infections: Nafcillin is commonly used to treat infections caused by Staphylococcus aureus bacteria, including:
Nafcillin-resistant Infections: Nafcillin is specifically effective against penicillinase-producing strains of Staphylococcus aureus. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA) or other methicillin-resistant strains.
Dosage and Administration: Nafcillin is usually administered intravenously (IV) or intramuscularly (IM) under the supervision of a healthcare provider. The dosage and duration of treatment depend on the severity and type of infection, as well as the patient's age, weight, and kidney function.
Adverse Effects: Common side effects of nafcillin may include:
Drug Interactions: Nafcillin may interact with other medications, including anticoagulants (blood thinners), oral contraceptives, and some other antibiotics. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting nafcillin therapy.
Monitoring: During treatment with nafcillin, patients may require monitoring of kidney and liver function, as well as monitoring for signs of allergic reactions or other adverse effects.
Resistance and Sensitivity Testing: Due to the emergence of antibiotic resistance, it is essential to perform culture and sensitivity testing before initiating nafcillin therapy to ensure its effectiveness against the specific bacterial strain causing the infection.
Duration of Treatment: The duration of nafcillin treatment varies depending on the type and severity of the infection. It is important to complete the full course of treatment as prescribed by your healthcare provider, even if symptoms improve before the medication is finished.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.1 | 0.1 |
| Allergies | 7.7 | 4.6 | 0.67 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 7.2 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.4 | 1.1 | 3 |
| Ankylosing spondylitis | 5 | 1.8 | 1.78 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 6.1 | 3.4 | 0.79 |
| Atherosclerosis | 2.3 | 3 | -0.3 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.5 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.6 | 2.6 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 2.8 | -2.11 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.2 | 4.3 | -0.34 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.2 | 6.9 | -0.11 |
| Chronic Kidney Disease | 4.6 | 3.4 | 0.35 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 2 | 0.25 |
| Chronic Urticaria (Hives) | 1.6 | 1.8 | -0.13 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 9.4 | 2.4 | 2.92 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.5 | 3 | -0.2 |
| COVID-19 | 10.6 | 13.7 | -0.29 |
| Crohn's Disease | 10 | 6.9 | 0.45 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 3.8 | 1.4 | 1.71 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.1 | 11.2 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.1 | 2.4 | 0.71 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.2 | 2.6 | 0.23 |
| Functional constipation / chronic idiopathic constipation | 6.5 | 4.3 | 0.51 |
| gallstone disease (gsd) | 3.9 | 1.6 | 1.44 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.5 | 3 | 0.17 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2 | 1.3 | 0.54 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2 | -1.22 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5 | 2.4 | 1.08 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.6 | 0.17 |
| hyperglycemia | 2.6 | 2.2 | 0.18 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.4 | 6.2 | -0.15 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.7 | 0.9 | 3.11 |
| IgA nephropathy (IgAN) | 1.9 | 4.9 | -1.58 |
| Inflammatory Bowel Disease | 10.6 | 11.2 | -0.06 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 1.6 | 0.6 | 1.67 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.4 | 6.4 | 0.31 |
| ischemic stroke | 3.3 | 1.7 | 0.94 |
| Liver Cirrhosis | 8.8 | 5.5 | 0.6 |
| Long COVID | 7.6 | 8.7 | -0.14 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 8 | 9.6 | -0.2 |
| Mood Disorders | 13.5 | 9.1 | 0.48 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9 | 7 | 0.29 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.1 | 5.9 | 0.03 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.8 | 10.6 | 0.11 |
| obsessive-compulsive disorder | 6.6 | 4.8 | 0.38 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.2 | 8.3 | 0.23 |
| Polycystic ovary syndrome | 7.5 | 3.7 | 1.03 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4 | 4 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.5 | 1.2 | -1.4 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 3.3 | 3.3 | 0 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 9.5 | 8.6 | 0.1 |
| Ulcerative colitis | 6.6 | 8.2 | -0.24 |
| Unhealthy Ageing | 6.9 | 2.9 | 1.38 |
| Vitiligo | 2.5 | 2 | 0.25 |
